Salt Lake City, UT, United States of America

Lipocine Inc.


USPTO Granted Patents = 48

% Expired Patents = 12.5



Trademarks = 3

Forward Citations = 5,988

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Mahesh V Patel (48 out of 99 patents)

silverMedal Nachiappan Chidambaram (30 out of 70 patents)

bronzeMedal Chandrashekar Giliyar (23 out of 33 patents)

4.  Basawaraj Chickmath (19 out of 26 patents)

5.  Srinivasan Venkateshwaran (15 out of 38 patents)

6.  Feng-Jing Chen (14 out of 14 patents)

7.  Satish Kumar Nachaegari (12 out of 27 patents)

8.  Srinivansan Venkateshwaran (11 out of 18 patents)

9.  Joel Frank (6 out of 16 patents)

10.  Benjamin J Bruno (5 out of 13 patents)

11.  Kilyoung Kim (5 out of 23 patents)

12.  Chidambaram Nachiappan (4 out of 5 patents)

13.  Jonathan Ogle (4 out of 8 patents)

14.  Kongnara Papangkorn (4 out of 10 patents)

15.  Samuel Akapo (3 out of 6 patents)


Core Competencies:
Hydroxyprogesterone
Allopregnanolone
Testosterone
CNS Disorders
Steroidal Compositions
Bioavailable Esters
Pharmaceutical Formulations
Drug Delivery
Hydrophobic Agents
Oral Dosage Forms
Active Ingredients

48 patents:

Lipocine Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on developing innovative therapies for metabolic and endocrine disorders. The company specializes in drug delivery systems, particularly utilizing its proprietary lipid-based technology to enhance the bioavailability of therapeutic compounds. Lipocine's research emphasizes the advancement of treatments for conditions such as testosterone deficiency, aiming to improve patient outcomes through effective and convenient medication options.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Lipocine Inc.
48 Patents

#25 in Salt Lake City, UT

#85 in Utah

#7,275 in US

#14,527 in the World

Salt Lake City, UT (US)
Salt Lake City, UT, United States of America
Forward Citations = 5,988

21 inventors:

Please report any incorrect information to [email protected]
Loading…